Phacilitate Leaders Forum

17th - 18th SEPTEMBER 2019



Ro  Wickramsinghe

Ro Wickramsinghe

Directory of Oncology Evaluation, AstraZeneca

Ro joined AstraZeneca in 2015 as an Evaluation Director in the Oncology Business Development team. He is responsible for leading the evaluation of new in-licensing and out-licensing opportunities in late stage oncology as well as Immuno-oncology clinical collaborations. Ro led the divestment of AstraZeneca’s rare disease thyroid cancer therapy Caprelsa to Sanofi/Genzyme for up to $300m. Ro has also led several Immuno-Oncology clinical collaboration deals including with Immunomedics combining IMFINZI (PD-L1 inhibitor) with IMMU-132 in first-line triple negative breast and bladder cancers, Celgene, NewLink Genetics, GSK and ADC Therapeutics.


Ro received his PhD in Oncology from Trinity College, Cambridge on a Gates Scholarship, and has an MBA from the Cambridge Judge Business School.

  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Jean-Philippe Combal
    GenSight Biologics
  • The conference consistently proves to be a great forum for networking with industry leaders in the development of cellular and gene therapies as well as vendors for important technologies and services.
    Michael Covington
    Juno Therapeutics, Inc
  • It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance
    Bertrand Alexandre
  • Phacilitate EU delivered it's promise and more, the topics discussed were highly relevant, with very good and professional speakers and panelists. You will see me next year in Berlin.
    Dr Ohad Karnieli
    Karnieli Ltd